Atypical oral candidiasis in a psoriatic patient during targeted immunotherapy with an interleukin 17 inhibitor (secukinumab)

BACKGROUND: Secukinumab is a human monoclonal antibody immunoglobulin that neutralises interleukin (IL)-17A, and as such, is effective in the treatment of psoriasis. However, as IL-17A is essential in protection against fungal infections, patients treated with this drug may develop candidiasis. This...

Descripción completa

Detalles Bibliográficos
Autores principales: Picciani, Bruna Lavinas Sayed, Dziedzic, Arkadiusz, Werneck, Juliana Tristão, Marinho, Marcello Alves, Dick, Thaylla Núñez Amin, Quintanilha, Nara Regina, Dias, Eliane Pedra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8186152/
https://www.ncbi.nlm.nih.gov/pubmed/34103043
http://dx.doi.org/10.1186/s12903-021-01653-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8186152/
https://www.ncbi.nlm.nih.gov/pubmed/34103043
http://dx.doi.org/10.1186/s12903-021-01653-6

Ejemplares similares